Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol soft-gel - Avecho Biotechnology

Next Previous
Drug Profile

Cannabidiol soft-gel - Avecho Biotechnology

Alternative Names: CBD soft-gel - Avecho Biotechnology; CBD-TPM®; TPM®-enhanced cannabidiol - Avecho Biotechnology

Latest Information Update: 02 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avecho Biotechnology
  • Class Alkenes; Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Cycloparaffins; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Phenols; Resorcinols; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Insomnia
  • Phase II Osteoarthritis

Most Recent Events

  • 29 Jun 2026 Avecho plans to engage with the US FDA and other international regulatory agencies to determine appropriate regulatory pathways for the product across specific geographic markets
  • 29 Jun 2026 Adverse events data from a phase III trial in Insomnia released by Avecho Biotechnology
  • 14 Mar 2024 Avecho Biotechnology plans a phase III trial for Insomnia in Australia in March 2024 (PO) (NCT05840822)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top